ClinicalTrials.gg
CompletedNCT05938075Updated Dec 10, 2024

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

A Phase 1 interventional study of VXCO-100 and COVID-19 mRNA vaccine in SARS-CoV and SARS-CoV-2, sponsored by Vaccine Company, Inc.. Completed at 2 sites in South Africa. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Vaccine Company, Inc. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Severe Acute Respiratory Syndrome with a site in South Africa — 1 open to participants now, 1 under way, 1 of them phase 3. Severe Acute Respiratory Syndrome · South Africa.

Enrollment
8th of 10
130 · median 1,665
Started
2023
the only one that year
Phase 1
2 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Vaccine Company, Inc.

Among the 11 studies in Severe Acute Respiratory Syndrome with a site in South Africa, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 1, and was the 11th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

1 of the 11 studies in Severe Acute Respiratory Syndrome with a site in South Africa is open now. Recruiting first, the newest first:

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Severe Acute Respiratory Syndrome with a site in South Africa, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.

Read the detailed description

This is a phase 1, multisite clinical trial to evaluate the safety and immunogenicity of 3 dose levels of VXCO-100 in adults.

Participants will be vaccinated with a selected dose of VXCO-100 or a COVID-19 mRNA vaccine. Participants will receive a dose of VXCO-100 on Day 1. A matched optional boost on month 6 will be offered to a subset of participants in Groups 1-3. Participants receiving a COVID-19 mRNA vaccine will be vaccinated on Day 1 and Day 21.

Safety will be evaluated before proceeding to a higher dose level.

03

Conditions studied

  • SARS-CoV
  • SARS-CoV-2

Keywords

  • Covid-19
  • SARS-CoV-2
  • Coronavirus
  • Vaccine
  • Sarbecoviruses
  • Covid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant must meet all the following criteria to be eligible for the study:

  1. Adults ages 18 years and older
  2. Judged by the investigator to be healthy based on participant-reported medical history, physical examination, vital signs, and laboratory assessment.
  3. Able to provide written .
  4. Willing to disclose prior COVID-19 vaccination status.
  5. Willing to disclose prior participant-reported SARS-CoV-2 infection status.
  6. Willing to comply with all study procedures during the follow-up period of approximately 12 months.
  7. of ≤ 40 kg/m2 within 30 days prior to enrollment
  8. (ECG) without abnormalities.
  9. Clinical screening laboratory evaluations (i.e., CBC, iron, ferritin, TIBC, , , AST, creatinine) are within acceptable normal reference ranges at the clinical laboratory being used or are not deemed clinically significant by study clinician.

    For participants of :

  10. Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on the day of enrollment
  11. Must agree to avoid pregnancy from 21 days prior to study Day 1 until at least 90 days after last study vaccination.

Exclusion criteria

Exclusion Criteria:

A participant will be excluded if one or more of the following conditions apply:

  1. Known SARS-CoV-2 infection or positive test result within 6 months prior to Day 1
  2. Ongoing prophylactic COVID-19 treatment, or monoclonal antibody infusion within 6 months prior to Day 1
  3. Any COVID-19 vaccination within 6 months prior to Day 1
  4. Exhibits symptoms consistent with COVID-19 as assessed by study clinician such as: fever, dry cough, fatigue, nasal obstruction, runny nose, sore throat, myalgia, diarrhea, shortness of breath or dyspnea within 14 days prior to in Day 1
  5. Known close contact (as defined by CDC, 2021a) with someone who has COVID-19 within 14 days prior to Day 1
  6. History or presence of self-reported or medically documented significant medical or psychiatric condition(s) as assessed by study clinician, including:

    1. At high risk of severe COVID-19 disease, such as significant history of or chronic lung disease, chronic kidney disease, serious heart conditions (such as heart failure, coronary artery disease or cardiomyopathies), sickle cell disease, diabetes
    2. central nervous system disease such as epilepsy, encephalopathy, or a history of severe mental illness
    3. Severe liver and/or kidney diseases, uncontrolled hypertension, or ongoing or highly likely to recur
    4. Ongoing or recent clinically significant history of alcohol or drug abuse
  7. Active participation in an interventional clinical study with an drug/biologic/device agent receipt of any specimen collection within 30 days prior to Day 1
  8. Evidence of infection with virus or virus
  9. Positive test result for (HIV) with the exception that 30% of participants may be HIV-infected, if stable on antiretrovirals with stable >350 cells/mm3 and virally suppressed
  10. History of myocarditis or pericarditis
  11. Diagnosed with congenital or acquired immune deficiency, ongoing lymphoma, leukemia, or other clinically significant immune compromising or conditions.
  12. History of known coagulation dysfunction (e.g., coagulation factor deficiency, known thrombocytopenia, dysfunction, coagulation disease, etc.)
  13. Receipt of any within 30 days, or with any other (non-live) vaccine within 14 days prior to Day 1
  14. Received more than 10 days of any systemic or cytotoxic medications within 30 days prior to Day 1, any within 14 days prior to Day 1 or is anticipating the need for immunosuppressants at any time during participation in the study.
  15. Received any blood products within 3 months prior to Day 1
  16. Donated > 450 mL of whole blood within 30 days prior to Day 1
  17. History of unexplained or recurrent anaphylaxis or angioedema, or a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any vaccine, or to any component of VXCO-100.
  18. For persons of : breastfeeding or planning to become pregnant during trial duration.
  19. Any condition that, in the opinion of the investigator, would (a) pose a health risk to the participant if enrolled or (b) could interfere with evaluation of the study vaccine or interpretation of study results.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    VXC0-100 at Dose level 1

    Participants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6.

    Biological: VXCO-100

  • Experimental
    VXC0-100 at Dose level 2

    Participants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6.

    Biological: VXCO-100

  • Experimental
    VXC0-100 at Dose level 3

    Participants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6.

    Biological: VXCO-100

  • Experimental
    COVID-19 mRNA vaccine

    Participants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21.

    Biological: COVID-19 mRNA vaccine

Interventions

  • BiologicalVXCO-100

    Sterile suspension for injection

  • Sterile suspension for injection

06

What researchers measure

Primary outcomes

  1. Number and percentage of participants with solicited local adverse events

    Time frame: For 7 days after each product administration

  2. Number and percentage of participants with solicited systemic adverse events

    Time frame: For 7 days after each product administration

  3. Number and percentage of participants with unsolicited and safety laboratory-based adverse events

    Time frame: For 28 days after each product administration

  4. Numbers and percentages of participants with serious adverse events (SAEs) including suspected unexpected serious adverse reactions (SUSARs), medically attended adverse events (MAAEs), and adverse events of special interest (AESIs)

    Time frame: For 364 days after each product administration

Secondary outcomes

  1. Response rate measured by geometric mean titer of the serum neutralizing antibody (Nab) against the ancestral (Wuhan) strain

    Time frame: At baseline and 21 days after each product administration

  2. Response rate measured by GMT of Nab against selected variants of concern

    Time frame: At baseline and 21 days after each product administration

  3. Numbers and percentages of participants with positive Th1 or Th2 cytokine responses for CD4 and CD8 as measured by multi-parameter intracellular cytokine staining

    Time frame: At baseline and 7 days after each product administration

07

Study locations

2 sites
  • Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital
    Johannesburg, Gauteng, South Africa
  • HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council
    Botha's Hill, Kwa-Zulu Natal, South Africa
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2024, 11 months.

Of 18 phase 1 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 10, 2023
StartActual
Aug 4, 2023
Primary completionActual
Jul 25, 2024
CompletionActual
Jul 25, 2024
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05938075
Lead sponsor
Vaccine Company, Inc.
Collaborators
Medical Research Council, South Africa
Responsible party
Sponsor
First posted
Jul 10, 2023
Start date
Aug 4, 2023
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024
Last update
Dec 10, 2024

Study contacts

Glenda Gray, MBChB, FC
principal investigator · Medical Research Council, South Africa
Ravindre Panchia, MBChB
principal investigator · Perinatal HIV Research Unit (PHRU)
Anusha Nana, BPharm
principal investigator · Perinatal HIV Research Unit (PHRU)
Mbalizethu Mntambo, MBChB
principal investigator · HIV and other Infectious Diseases Research Unit (HIDRU)
Samantha Siva, MMEDSc
principal investigator · HIV and other Infectious Diseases Research Unit (HIDRU)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion